Colchicine is a competitive antagonist at human recombinant gamma-aminobutyric acidA receptors. by Weiner, J. L. et al.
Colchicine Is a Competitive Antagonist at Human Recombinant
g-Aminobutyric AcidA Receptors
1
J. L. WEINER, A. V. BUHLER, V. J. WHATLEY, R. A. HARRIS and T. V. DUNWIDDIE
Department of Pharmacology (J.L.W., A.V.B., V.J.W., R.A.H., T.V.D.) and Program in Neuroscience (R.A.H., T.V.D.), University of Colorado
Health Sciences Center, Denver, Colorado, and Veterans Administration Medical Center (R.A.H., T.V.D.), Denver, Colorado
Accepted for publication September 15, 1997 This paper is available online at http://www.jpet.org
ABSTRACT
Colchicine is an alkaloid that is used clinically in the treatment
of arthritic gout. This potent microtubule disrupting agent has
also been used extensively as an experimental tool in studies
characterizing the role of the cytoskeleton in a variety of cellular
processes. Colchicine has also been used as a selective neu-
rotoxin and in animal models of Alzheimer’s disease and epi-
lepsy. Although the mechanism(s) mediating the neurotoxic
actions of colchicine have not been established, most studies
have attributed these effects to its microtubule depolymerizing
actions. Here we report another central nervous system action
of colchicine, competitive antagonism of g-aminobutyric acid
(GABA)A receptor function. By use of a rapid drug perfusion
system, colchicine (10–1000 mM) significantly inhibited GABA
currents recorded from L(tk2) cells stably transfected with hu-
man a1b2g2L GABAA receptor subunits. The inhibition was
rapid and reversible, with 100 mM colchicine shifting the GABA
EC50 from 2.5 to 5.1 mM with no effect on currents evoked by
saturating concentrations of GABA. Colchicine also signifi-
cantly inhibited binding of the competitive GABAA receptor
antagonist [3H]SR-95531. Other microtubule disrupting agents
(10 mM vinblastine, 10 mg/ml nocodazole, 1 mM taxol) had no
acute effects on GABA currents, nor did the inactive analog
g-lumicolchicine (100 mM). Moreover, pretreating cells with col-
chicine, vinblastine, nocodazole or taxol for 1 to 4 hr did not
occlude the acute inhibitory action of colchicine. We conclude
that, in addition to its well characterized effects on microtubule
assembly, colchicine can also inhibit GABAA receptor function
through a direct interaction with the receptor/ion channel com-
plex.
Colchicine is a plant-derived alkaloid that binds to tubulin
and depolymerizes microtubules (Osborn and Weber, 1976;
Walker and Whitfield, 1985), disrupts axonal transport
(Karlsson and Sjostrand, 1969; Fink et al., 1973; Wooten et
al., 1975) and inhibits mitosis (Wilson and Friedkin, 1966,
1967; Wang et al., 1975). This compound has been used
clinically in the treatment of gout (Hastie, 1991) and has also
been used extensively as an experimental tool to characterize
cellular processes that involve microtubule structure and
axoplasmic transport (Chiaia et al., 1996; Schmalz et al.,
1996; Tandon et al., 1996; Saib et al., 1997). Numerous stud-
ies have also used colchicine as a neurotoxin to cause lesions
in discrete brain regions, such as the dentate gyrus (Brady et
al., 1992; Newell et al., 1993; Tandon et al., 1994; Gobbi et al.,
1996) and the septum (Peterson and McGinty, 1988; Gilbert
and Peterson, 1991), and several recent studies have sug-
gested that colchicine neurotoxicity may model some of the
neuropathological aspects of Alzheimer’s dementia (Naka-
gawa et al., 1987; Mattson, 1992). In all of these cases, the
mechanism of colchicine action has been attributed to its
inhibition of tubulin binding and subsequent disruption of
processes that depend on the integrity of cytoskeletal archi-
tecture. However, the mechanism(s) underlying these diverse
actions of colchicine have not been determined experimen-
tally.
Several studies have also demonstrated that colchicine can
significantly inhibit the function of several ion channels,
including voltage-gated sodium (Matsumoto et al., 1984) and
calcium (Johnson and Byerly, 1993) channels and ligand-
gated nicotinic (Hardwick and Parsons, 1995) and GABAA
receptor-gated ion channels (Whatley et al., 1994; Whatley
and Harris, 1996). The mechanism(s) through which colchi-
cine exerts these effects are unclear, but have been hypoth-
esized to involve the depolymerizing actions of this drug.
We have characterized the interaction of colchicine and
other microtubule disrupting agents with recombinant
GABAA receptors in a stable transfection system to further
delineate the mechanism(s) through which microtubule de-
polymerization might inhibit GABAA receptor function. Here
we report that colchicine appears to have an additional direct
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inhibitory effect on GABAA receptor function, one that is
independent of the microtubule disrupting actions of this
drug. Unlike the indirect inhibition of GABAA receptor func-
tion that appears to be related to effects on microtubules
(Whatley et al., 1994; Whatley and Harris, 1996), this direct
effect is rapid and competitive, and it is not mimicked or
occluded by other microtubule disrupting agents.
Materials and Methods
Cell culture conditions. Stable transfection of mouse L (tk2)
cells with human GABAA receptor subunits was carried out as de-
scribed previously (Hadingham et al., 1992). Expression was con-
trolled by a dexamethasone-sensitive promoter. Cells were grown to
confluence in 75-ml flasks and then plated onto 12-mm-diameter
glass coverslips coated with poly-L-lysine with Dulbecco’s Modified
Eagle’s Medium (DME/high glucose, Hyclone, Logan, UT) supple-
mented with 10% fetal bovine serum (Gemini Bio-Product, Calaba-
sas, CA), 100 U/ml penicillin, 0.1 mg/ml streptomycin (Sigma Chem-
icals, St. Louis, MO) and 2 mM L-glutamine (Dexter CO/Gibco Labs
Division, Grand Island, NY). Cells were grown on coverslips for 24 to
48 hr at 37°C/5% CO2, treated with 1 mM dexamethasone (Sigma
Chemical, St. Louis, MO) and then grown for an additional 3 to 6
days.
Electrophysiology. Coverslips were transferred to a recording
chamber perfused with a HEPES-buffered external solution (in mM):
NaCl, 130; KCl, 5; CaCl2, 2; MgCl2, 1; HEPES, 10; D-glucose, 11; pH
adjusted to 7.4 with NaOH; 300–310 mOsm. Whole-cell patch re-
cordings were made from individual cells with borosilicate glass
electrodes (1.5 mm outer diameter, 0.86 mm internal diameter, Sut-
ter Instruments, Novato, CA). The intracellular recording solution
contained (in mM): KCl, 130; CaCl2, 0.1; EGTA, 1.0; Mg-ATP, 2;
Tris-GTP, 0.2; HEPES, 10; pH adjusted with KOH; 275–285 mOsm.
Currents were recorded with an Axopatch 200 amplifier (Axon In-
struments, Foster City, CA), low pass filtered with a 4 pole Bessel
Filter (2 KHz) and analyzed on- and off-line with software developed
in this laboratory. All external solutions were gravity fed from glass
12-cc syringe reservoirs through a two-barrel flow tube array (450
mm internal diameter, Polymicro Tech. Inc., Phoenix, AZ). The flow
tube array was affixed to a piezoelectric double ceramic plate (Bi-
morph) (Morgan Matroc, Inc., Bedford, OH). By applying a voltage
across the Bimorph, the solution interface across the surface of the
cell being recorded could be rapidly exchanged (approximately 100
msec half-time). Cells were voltage-clamped at –40 to –60 mV and
inward currents were evoked by 2- or 3-sec applications of GABA at
an interval of 30 or 60 sec. Unless otherwise indicated, all drugs were
applied only during the GABA pulses.
[3H]SR 95531 binding. For analysis of [3H]SR 95531 binding,
cells stably transfected with recombinant subunits were harvested
and prepared as described previously (Klein et al., 1994). Cells were
homogenized in assay buffer (in mM): NaCl, 145; KCl, 5; MgCl2, 1;
CaCl2, 1; D-glucose, 10; HEPES, 10; pH adjusted to 7.5 with Tris
base, pelleted twice at 100,000 3 g for 15 min and resuspended in
assay buffer. [3H]SR 95531 binding was performed essentially as
described by Buck and Harris (1990). Aliquots of cell membrane
(150–250 mg protein) were incubated with 3 nM [3H]SR 95531, 3 to
300 nM nonradioactive SR 95531 plus/minus 100 mM colchicine in a
final volume of 0.3 ml for 30 min at 34°C. Nonspecific binding was
determined in the presence of 100 mM GABA.
Drugs. Unless otherwise stated, all reagents used in the electro-
physiological experiments were purchased from Sigma Chemicals
(St. Louis, MO). The reagents used in the intracellular recording
solution were purchased from Fluka (Buchs, Switzerland), except
Mg-ATP and Tris-GTP. Taxol and vinblastine were purchased from
Calbiochem (La Jolla, CA), and flumazenil from Hoffman-LaRoche
(Nutley, NJ). Flumazenil and all microtubule disrupting agents were
made up as concentrated stock solutions in 100% DMSO, stored at
–20°C and diluted to their final concentrations immediately before
each experiment. The final concentration of DMSO never exceeded
0.1%, a concentration that had no effect on GABA currents in this
study.
Statistics. Drug effects were quantified as the percent change in
GABA-evoked current amplitude relative to the mean of control and
washout values. Statistical analyses of drug effects were performed
by two-tailed Student’s paired and unpaired t tests as indicated, with
a minimal level of significance of P , .05. pA2 values for colchicine
inhibition were estimated from the electrophysiological and binding
assays with the dose ratio of EC50 concentrations of GABA in the
presence and absence of 100 mM colchicine.
Results
Colchicine rapidly antagonizes GABA-evoked cur-
rents. All recordings were carried out on murine L(tk2) cells
stably transfected with human recombinant a1b2g2L
GABAA receptor subunits. Three to six days after dexameth-
asone induction of GABAA receptor expression, rapid appli-
cation of GABA reliably generated dose-dependent inward
currents in cells voltage-clamped at -40 to -60 mV. These
responses reversed at the chloride equilibrium potential (0
mV under our recording conditions), were completely antag-
onized by 20 mM bicuculline (data not shown) and were
therefore mediated by the activation of GABAA receptors.
The effect of colchicine was initially determined on cur-
rents evoked by a half-maximal concentration of GABA (2
mM). Colchicine was applied continuously for a 10-min pe-
riod, during which GABA currents were evoked every 30 sec.
With this protocol, 100 mM colchicine caused a rapid inhibi-
tion of GABA-evoked currents (fig. 1). The mean inhibition
was 63 6 5% (n 5 6; P , .01, paired t test) and both the onset
and washout of the inhibition exhibited a latency of less than
1 to 2 min, which was similar to the time required to intro-
duce a new drug through the drug delivery system. To deter-
mine whether the continuous colchicine application was nec-
essary to observe the inhibition, a protocol was used in which
100 mM colchicine was applied concurrently with the GABA
applications (fig. 1). The inhibition observed with this proto-
col (61 6 2%, n 5 13) was not statistically different from that
observed with continuous application of colchicine (P . .5,
unpaired t test).
To further resolve the time course of colchicine inhibition,
we next used a protocol in which the solution bathing the cell
was stepped from a low concentration of GABA (200–500 nM)
to one containing the same concentration of GABA plus 100
mM colchicine. The latency of the resulting change in current
amplitude was therefore limited only by the kinetics associ-
ated with colchicine inhibition and the time required to ex-
change the solution interface across the cell being recorded.
With this protocol, colchicine inhibited the GABA-evoked
currents with onset and offset half-times of approximately
140 msec (fig. 2A). Although the rapid perfusion system used
in this study could effectively exchange the solution at the tip
of the electrode with a half-time of ,10 msec, the time re-
quired to equilibrate a solution exchange across a whole cell
was considerably slower (50–100 msec). We therefore com-
pared the kinetics of colchicine inhibition with that induced
by an equieffective concentration of bicuculline methiodide, a
well-characterized competitive antagonist of GABAA recep-
tors (fig. 2B). No difference was observed between the onset
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and offset kinetics of bicuculline inhibition and that of col-
chicine.
Colchicine inhibition of GABA-evoked currents is
dose-dependent and competitive. A separate series of
experiments were carried out to characterize the pharmaco-
logical characteristics of the colchicine antagonism of GABAA
receptor-mediated responses. With use of the concurrent ap-
plication protocol, the colchicine inhibition of currents evoked
by 2 mM GABA was dose-dependent, with an EC50 of 56 mM
and a Hill coefficient of 1.2 (fig. 3). The lowest concentration
of colchicine that significantly inhibited currents evoked by 2
mM GABA was 10 mM (14 6 2%, P , .01, paired t test, n 5 7),
and a concentration of 1 mM colchicine almost completely
antagonized these currents.
The acute effect of 100 mM colchicine was next tested
across a full range of GABA concentrations. Colchicine pro-
duced greater than 80% inhibition of currents evoked by an
EC10 concentration of GABA but had almost no effect at
saturating GABA concentrations (fig. 4A). Colchicine signif-
icantly shifted the GABA dose-response curve to the right,
Fig. 1. Acute application of colchicine inhibits
GABAA receptor-gated chloride currents. The
time course of 100 mM colchicine inhibition of
currents evoked by 2 mM GABA with (f) and
without colchicine preincubation is illustrated
at the bottom. Traces at the top are averages of
three to seven sweeps recorded at the times
indicated by corresponding letters on the graph.
The solid bars above the averages represent the
time during which GABA was applied via the
flow tubes, and the unfilled bars indicate the
duration of colchicine application. Note that
filled circles indicate application of 2 mM GABA
and unfilled circles indicate concurrent applica-
tion of 100 mM colchicine and 2 mM GABA. The
apparent slow onset of the effects of colchicine
on the GABA response reflects the time re-
quired to change the solutions in the flow tubes;
once this has occurred, colchicine can antago-
nize the GABA response within 100 to 200 msec
of its application (e.g., in D; see also fig. 2).
Fig. 2. Rapid time course of colchicine and
bicuculline inhibition of GABA-evoked currents.
The time course of the reduction in inward cur-
rent elicited by a 2-sec application of 100 mM
colchicine (A) or 1 mM bicuculline (B) during
continuous application of 500 nM GABA is
shown. Note that 500 nM GABA was present
throughout the entire period and that both the
onset and offset of the inhibition were identical
for both drugs.
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increasing the GABA EC50 from 2.5 6 0.3 mM to 5.1 6 0.5 mM
(paired t test, P , .001, n 5 6) with no significant change in
the Hill coefficient (control 5 1.2 6 0.1; colchicine 5 1.3 6
0.2, P . .3, paired t test, n 5 6). The estimated pA2 value for
colchicine was 4.02, corresponding to an IC50 of 96 mM.
To confirm that colchicine was a competitive antagonist at
the GABA binding site, the effect of colchicine on [3H]SR
95531 binding to membranes of cells expressing a1b1g2L
GABAA receptor subunits was determined (table 1). Colchi-
cine (100 mM) significantly increased the KD of [
3H]SR 95531
binding (control 5 37 6 3 nM; colchicine 5 101 6 9 nM; P ,
.001) with no effect on the Bmax (control 5 0.4 6 0.1; colchi-
cine 5 0.6 6 0.1) or Hill coefficient (0.9 6 0.1; colchicine 5
0.9 6 0.1; table 1). The estimated Ki value for colchicine
calculated from the binding assay was 58 mM.
The colchicine inhibition does not involve the benzodiaz-
epine binding site. b-Lumicolchicine is a structural analog of col-
chicine that has no effect on microtubules (Wilson and Friedkin,
Fig. 3. Dose dependence of colchicine in-
hibition of GABA-evoked currents. The
mean inhibition of currents evoked by 2
mM GABA by 1 to 1000 mM colchicine is
shown; each point is the mean 6 S.E.M.
obtained from between 4 and 13 cells.
Traces at the top of the figure are aver-
ages of three to six sweeps recorded from
a single representative cell during acute
application of 10 mM, 50 mM and 1 mM
colchicine (COL). CTL 5 control.
Fig. 4. Colchicine antagonizes GABAA
receptor function in a competitive man-
ner. (A) Representative traces illustrate
the effects of 100 mM colchicine (COL) on
currents evoked by 500 nM, 2 mM and 10
mM GABA. Note that the magnitude of
the colchicine inhibition decreases with
increasing GABA concentrations. (B) Ef-
fect of colchicine on the GABA dose-re-
sponse curve. Each point represents the
mean 6 S.E.M. from 3 to 13 cells tested at
each concentration. In some cases, error
bars fall within the symbols.
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1967; Walker and Whitfield, 1985). A previous report demonstrated
that this analog potentiated GABAA receptor function by a direct
interaction with the benzodiazepine site on GABAA receptors (Mihic
et al., 1994). We therefore determined whether the antagonism of
GABAA receptor function observed with colchicine was mediated by
an interaction with this same site. Under the recording conditions
used in this study, acute application of 100 mM b-lumicolchicine
significantly potentiated currents evoked by 1 mM GABA in cells
expressing a1b2g2L GABAA receptor subunits (fig. 5). The mean
potentiation was 147 6 4% (P , .001, paired t test, n 5 5) and this
enhancement was completely blocked by flumazenil. Colchicine (100
mM) significantly inhibited GABA currents, as observed in the initial
experiments, however flumazenil had no effect on the colchicine
inhibition (fig. 5).
Other microtubule disrupting agents do not mimic or oc-
clude the acute actions of colchicine. The acute effects of other
microtubule disrupting agents were also tested by the same protocol
used for colchicine. We tested the acute actions of 10 mM vinblastine,
1 mM taxol and 10 mg/ml nocodazole on currents evoked by 2 mM
GABA. None of these compounds had any significant effect on
GABA-evoked currents (fig. 6). We also tested another inactive an-
alog of colchicine, g-lumicolchicine, which was also without effect on
GABA-evoked currents.
We next tested whether microtubule depolymerization could oc-
clude the acute inhibitory effect of colchicine on GABAA receptor
function. In an initial series of experiments, cells were preincubated
with 100 mM colchicine for 1 to 4 hr, a protocol that has previously
been shown to maximally depolymerize microtubules in these cells
(Whatley and Harris, 1996; Whatley et al., submitted). Cells were
then patch-clamped with the standard intracellular recording solu-
tion in the continuous presence of colchicine. After obtaining a stable
base-line current evoked by 2 mM GABA, the colchicine was then
washed off. This resulted in a rapid potentiation of the current
presumably caused by a washout of the acute inhibitory effect of
colchicine. Once a new base line was obtained (2–4 min), the acute
effect of 100 mM colchicine was assessed. No difference was observed
between the acute effect of 100 mM colchicine on control cells and
cells pretreated with colchicine. (The inhibition of the GABA re-
sponse was 61 6 2%, n 5 13 vs. 66 6 3%, n 5 6, P . .2, unpaired t
test.) (fig. 7).
In a second set of experiments, we tested whether prolonged
treatment with other microtubule disrupting agents could occlude
the acute effects of colchicine. In preliminary experiments, continu-
ous application of 10 mg/ml nocodazole or 1 mM taxol for 20 to 30 min
had no effect on GABA-evoked currents. However, a 20-min applica-
tion of 100 mM vinblastine did significantly inhibit these responses
(Whatley et al., submitted). These disparate effects may reflect dif-
ferences in the time required for these compounds to depolymerize
microtubules under our recording conditions. Because the microtu-
bule depolymerizing actions of these drugs require at least 60 min
(Whatley and Harris, 1996; Whatley et al., submitted) and we cannot
routinely maintain stable recordings for that long, cells were prein-
cubated with 10 mg/ml nocodazole, 1 mM taxol or 100 mM vinblastine
for 1 to 4 hr before electrophysiological recordings to ensure that
these compounds had sufficient time to maximally depolymerize
microtubules (Whatley and Harris, 1996; Whatley et al., submitted).
After the drug pretreatments, the effect of concurrent application of
100 mM colchicine and 2 mM GABA was assayed in the continuous
presence of these compounds. None of these pretreatments had any
effect on the inhibitory action of 100 mM colchicine on GABA-evoked
currents (fig. 7.).
TABLE 1
Effect of colchicine on [3H]SR 95531 binding in L(tk2) cells expressing
a1b2g2L GABAA receptor subunits
a
Treatment KD Bmax Hill Coefficient
nM pmol/mg
Control 37.0 6 2.6 0.4 6 0.1 0.95 6 0.03
Colchicine (100 mM) 101.0 6 9.4* 0.6 6 0.1 0.91 6 0.04
a Values are mean 6 S.E.M. of 3 to 12 experiments, each carried out in triplicate.
* P , .001.
Fig. 5. Colchicine inhibition does not in-
volve the benzodiazepine binding site. (A)
Representative traces illustrating the ef-
fect of 1 mM flumazenil on the enhance-
ment of GABA responses induced by 100
mM b-lumicolchicine and on the antago-
nism of GABA responses induced by 100
mM colchicine. (B) Bar graph summarizing
the effect of 100 mM b-lumicolchicine and
100 mM colchicine on GABA-evoked cur-
rents in the presence and absence of 1 mM
flumazenil. n 5 3–7 cells/group. Note that
flumazenil completely antagonized the
b-lumicolchicine-induced potentiation of
GABA-evoked currents but had no effect
on the colchicine-mediated inhibition.
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Discussion
The results of this study demonstrate that colchicine can
act as a competitive antagonist at GABAA receptors through
a mechanism that appears to be distinct from the effects of
this drug on microtubule depolymerization. Two studies have
previously demonstrated that colchicine and other microtu-
bule depolymerizing agents can inhibit GABAA receptor
function in cerebral cortical microsacs, in Xenopus oocytes
transiently transfected with recombinant GABAA receptor
subunits (Whatley et al., 1994) and in cells stably transfected
with GABAA receptor subunits (Whatley et al., submitted). In
both of these studies, this inhibition was attributed to the
depolymerizing actions of these compounds on microtubule
structure. However the time course and characteristics of the
inhibition were significantly different. In microsacs and oo-
cytes, 100 mM colchicine inhibited GABAA receptor function
in as little as 3 to 20 sec and the inhibition appeared to be
competitive. Other microtubule depolymerizing drugs also
inhibited GABAA receptor-mediated chloride flux, although
their actions were only characterized at 30 to 60 min. In
contrast, in chloride flux studies of the stably transfected cell
line characterized in the present study, 100 mM colchicine
required 60 min to significantly inhibit GABAA receptor func-
tion, and this inhibition was noncompetitive, having no effect
on GABAA receptor affinity. Moreover, using immunolabel-
ing of tubulin, it was shown that colchicine did not apprecia-
bly depolymerize microtubule structure for at least 30 min.
Based on the results of these studies, it is clear that colchi-
cine (but not the other depolymerizing agents) has a direct,
competitive inhibitory interaction with the GABAA receptor
Fig. 6. Other microtubule disrupting compounds have
no acute effect on GABA-evoked currents. The bar graph
summarizes the acute effect of 100 mM colchicine (COL),
100 mM g-lumicolchicine (g-Lumi), 10 mM vinblastine
(VIN), 1 mM taxol and 10 mg/ml nocodazole (NOCOD) on
currents evoked by 2 mM GABA. n 5 5–12 cells/group.
Fig. 7. Disruption of microtubules does not oc-
clude the acute effect of colchicine. The bar
graph summarizes the acute effect of colchicine
under control conditions (white bar), and after
incubation of cells for 1 to 4 hr with 100 mM
colchicine (COL), 10 mM vinblastine (VIN), 1
mM taxol or 10 mg/ml nocodazole (NOCOD). n 5
4–12 cells/group.
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that is apparent within 100 msec of colchicine application,
and does not involve the microtubule depolymerizing actions
of this drug. In contrast, the noncompetitive inhibitory ef-
fects of colchicine and other similar agents that are observed
at longer treatment intervals ($60 minutes) are likely to
involve a mechanism related to the depolymerizing actions of
these drugs.
Several lines of evidence indicate that the inhibition of
GABAA receptor function observed in this study did not in-
volve the microtubule depolymerizing actions of colchicine.
First, the time course of the colchicine inhibition of GABA-
evoked currents is inconsistent with the microtubule depoly-
merizing actions of this drug (Whatley and Harris, 1996;
Whatley et al., submitted). With concurrent application of
colchicine and GABA, the inhibition developed with a half-
time of approximately 140 msec, whereas colchicine-medi-
ated microtubule depolymerization in these cells required at
least 30 min (Whatley et al., submitted). In addition, within
the temporal resolution of the drug delivery system used in
this study, no difference was observed between colchicine
antagonism of GABA-evoked currents and that produced by
equieffective concentrations of bicuculline methiodide, a com-
petitive GABAA receptor antagonist. Second, the effects of
colchicine in the present study were characterized by a com-
petitive interaction with GABA, whereas the inhibition at-
tributed to depolymerization produces a noncompetitive de-
crease in GABA efficacy with no change in receptor affinity
for GABA (Whatley et al., submitted). Third, the rapid inhib-
itory effect of colchicine on GABA-evoked currents was not
observed with other microtubule disrupting agents like no-
codazole, vinblastine and taxol. In contrast, all three of these
compounds have been shown to significantly inhibit GABAA
receptor function when applied for durations that are suffi-
cient to depolymerize microtubule assembly (Whatley et al.,
1994; Whatley and Harris, 1996). Finally, prolonged incuba-
tion of cells in colchicine or other microtubule depolymerizing
drugs for durations that were long enough to fully depoly-
merize microtubules in these cells (Whatley and Harris,
1996; Whatley et al., submitted) had no effect on the rapid
colchicine inhibition of GABAA receptor function, which
again suggests the independence of these two actions.
The results of this study suggest that colchicine is a com-
petitive antagonist at GABAA receptors, an action that is
independent from the noncompetitive colchicine inhibition
associated with the microtubule depolymerizing actions of
this drug. Presently, the mechanism by which colchicine
exerts this effect is not known. Colchicine may inhibit
GABAA receptor function by direct interaction with the
GABA binding site or alternatively it may modulate GABA
affinity via an allosteric interaction with another site on the
GABAA receptor or even with some protein closely associated
with it. This latter possibility, that colchicine is acting as an
allosteric, apparent competitive antagonist, is supported by
the observation that colchicine had no effect on GABAA re-
ceptors reconstituted into proteoliposomes (Whatley et al.,
1994) where any proteins that might normally associate with
these receptors in neurons would not be present. There is
evidence that a structural analog of colchicine, b-lumicolch-
icine, can interact directly with the benzodiazepine binding
site on GABAA receptors (Mihic et al., 1994). This analog does
not bind tubulin and is therefore often used as a control for
the microtubule disrupting actions of colchicine. However,
b-lumicolchicine was shown to compete with flunitrazepam
binding in cerebral cortical microsacs and potentiate musci-
mol-stimulated chloride flux in microsacs and GABA-evoked
currents in Xenopus oocytes stably transfected with recom-
binant GABAA receptor subunits (Mihic et al., 1994). In ad-
dition, the potentiation of GABA-evoked currents was com-
pletely antagonized by flumazenil, a competitive
benzodiazepine antagonist. In the present experiments, sim-
ilar effects of b-lumicolchicine on GABA-evoked currents
were observed, but the acute inhibitory effect of colchicine
was not antagonized by flumazenil. This suggests that col-
chicine and b-lumicolchicine, despite being structural ana-
logs, do not interact with the same site on the GABAA recep-
tor complex.
In preliminary experiments, continuous application of mi-
crotubule disrupting drugs such as nocodozole and taxol for
up to 30 min did not significantly inhibit GABA-evoked cur-
rents. Similar treatments with colchicine did inhibit GABAA
receptor function; however, this inhibition could all be attrib-
uted to the acute, competitive inhibition that appears to be
independent of colchicine’s microtubule depolymerizing ef-
fects. In contrast, a 20-min continuous application of vinblas-
tine did significantly inhibit GABA responses (Whatley et al.,
submitted). These disparate findings may reflect differences
in the depolymerization kinetics of these compounds under
our experimental conditions; however, incubating cells for up
to 4 hr with these compounds, an interval sufficient to ensure
maximal microtubule depolymerization (Whatley and Har-
ris, 1996; Whatley et al., submitted), had no effect on the
acute inhibitory action of colchicine.
Colchicine has been used as an experimental tool in nu-
merous studies to characterize the role of microtubule assem-
bly in various aspects of cellular function (Chiaia et al., 1996;
Schmalz et al., 1996; Tandon et al., 1996; Saib et al., 1997)
and as a selective neurotoxin in studies of epilepsy (Lee and
Hong, 1990; Barnes and Mitchell, 1993; Gobbi et al., 1996)
and Alzheimer’s disease (Nakagawa et al., 1987; Mattson,
1992). The mechanism underlying the neurotoxic effects of
colchicine is not known, but has usually been attributed to its
ability to disrupt microtubule assembly, because structural
analogs of colchicine, such as b- and g-lumicolchicine, that do
not bind tubulin, do not mimic the neurotoxic effects of col-
chicine.
Our findings suggest that at least some of the neurotoxic
actions of colchicine may be a result of direct inhibition of
GABAA receptor function. This is particularly likely in those
studies in which colchicine was injected directly into specific
brain regions to induce seizures (Lee and Hong, 1990; Barnes
and Mitchell, 1993; Gobbi et al., 1996). Other competitive
GABAA receptor antagonists can elicit seizures in vivo and
frequently have been used in models of epileptogenesis (Ue-
mura and Kimura, 1988; Cataltepe et al., 1995; Reigel and
Bourn, 1995). In addition, some of the neuropathological
actions of colchicine on the phosphorylation state of the mi-
crotubule-associated protein, tau, are also observed with glu-
tamate administration (Nakagawa et al., 1987; Mattson,
1992) and are not mimicked by other microtubule disrupting
agents (Sygowski et al., 1993). These effects may stem from a
generalized increase in neuronal excitability resulting, in the
case of glutamate, from direct activation of (6)-a-amino-3-
hydroxy-5-methylisoxazole-4-proprionic acid and/or N-meth-
yl-D-aspartate receptors and, in the case of colchicine, from
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acute inhibition of GABAA receptor function. Preliminary
experiments from our laboratory have shown that colchicine,
at concentrations used in this study, can significantly de-
press GABAA receptor-mediated synaptic currents in rat hip-
pocampal CA1 neurons. These findings further support the
hypothesis that direct antagonism of neuronal GABAA recep-
tor function may underlie some of colchicine’s neurotoxic
actions.
Our results also suggest that the use of structural analogs
of colchicine that do not bind tubulin may not be sufficient to
demonstrate that effects of colchicine are mediated by micro-
tubule depolymerization. Because these analogs either po-
tentiate (b-lumicolchicine) or have no acute effect (g-lumi-
colchicine) on GABAA receptor function, they would not
mimic the effects of colchicine that reflect its acute inhibitory
action on GABAA receptor function. Because other microtu-
bule disrupting agents, such as nocodazole, taxol and vin-
blastine, do not share this acute inhibitory effect on GABAA
receptor function, these agents may prove more useful in
identifying the actions of colchicine that are mediated by
depolymerization of microtubules. A detailed understanding
of the cellular substrates that underlie colchicine-mediated
neurotoxicity is needed to evaluate and interpret the results
of studies that use this compound in animal models of com-
plex disease states such as epilepsy and Alzheimer’s disease.
Further studies will be needed to determine the extent to
which competitive antagonism of GABAA receptors contrib-
utes to the neuropathological actions of colchicine.
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